Citadel Advisors
IMUX icon

Citadel Advisors’s Immunic IMUX Stock Holding History

Citadel Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.7K Sell
3,130
-920
-23% -$8.24K ﹤0.01% 12533
2025
Q4 		$21.6K Sell
4,050
-740
-15% -$5.42K ﹤0.01% 12326
2025
Q3 		$42.2K Buy
4,790
+3,010
+169% +$26.5K ﹤0.01% 12273
2025
Q2 		$12.4K Sell
1,780
-3,580
-67% -$32.9K ﹤0.01% 12180
2025
Q1 		$58.4K Sell
5,360
-8,270
-61% -$89.3K ﹤0.01% 12143
2024
Q4 		$136K Buy
13,630
+4,710
+53% +$59.3K ﹤0.01% 11026
2024
Q3 		$147K Buy
8,920
+630
+8% +$8.97K ﹤0.01% 10587
2024
Q2 		$92K Buy
8,290
+770
+10% +$9.56K ﹤0.01% 11035
2024
Q1 		$99.3K Sell
7,520
-390
-5% -$5.07K ﹤0.01% 11367
2023
Q4 		$119K Buy
7,910
+2,740
+53% +$33.6K ﹤0.01% 10714
2023
Q3 		$76K Sell
5,170
-770
-13% -$14.8K ﹤0.01% 11231
2023
Q2 		$149K Sell
5,940
-3,600
-38% -$60.3K ﹤0.01% 10352
2023
Q1 		$142K Buy
9,540
+5,150
+117% +$95.6K ﹤0.01% 10731
2022
Q4 		$61.5K Buy
4,390
+1,960
+81% +$53.5K ﹤0.01% 11887
2022
Q3 		$77K Sell
2,430
-1,740
-42% -$72.8K ﹤0.01% 11306
2022
Q2 		$145K Sell
4,170
-1,150
-22% -$73.7K ﹤0.01% 11015
2022
Q1 		$601K Buy
+5,320
New +$616K ﹤0.01% 8952
2021
Q3 		– Sell
-1,810
Closed -$222K – 14209
2021
Q2 		$222K Buy
+1,810
New +$250K ﹤0.01% 11932
2019
Q1 		– Sell
-50
Closed -$4K – 9561
2018
Q4 		$4K Sell
50
-237
-83% -$27.7K ﹤0.01% 8990
2018
Q3 		$32K Buy
287
+224
+356% +$585K ﹤0.01% 8907
2018
Q2 		$173K Buy
+63
New +$146K ﹤0.01% 7995
2016
Q1 		– Sell
-6
Closed -$25K – 7321
2015
Q4 		$25K Sell
6
-3
-33% -$9.79K ﹤0.01% 7785
2015
Q3 		$14K Sell
9
-4
-31% -$20K ﹤0.01% 8351
2015
Q2 		$110K Buy
+13
New +$124K ﹤0.01% 6989

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Citadel Advisors's IMUX Position: Q1 2026 in Review

Citadel Advisors reduced its Immunic (IMUX) stake by 57% in Q1 2026, selling an estimated $136K and leaving 11,449 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #11827.

Citadel Advisors first reported a position in IMUX in Q2 2015 and has held it in 21 quarters since. The position peaked at $1.72M in Q2 2022. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Citadel Advisors held 11,449 shares of Immunic worth $127K as of Q1 2026.
  • Citadel Advisors sold 15,232 Immunic shares in Q1 2026, an estimated $136K.
  • Immunic made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11827 holding.
  • Citadel Advisors first reported a position in Immunic in Q2 2015 and has held it in 21 quarters since.
  • Citadel Advisors's Immunic position peaked at $1.72M in Q2 2022.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.